192 related articles for article (PubMed ID: 37097390)
21. Clinical and biological significance of hepatoma-derived growth factor in Ewing's sarcoma.
Yang Y; Li H; Zhang F; Shi H; Zhen T; Dai S; Kang L; Liang Y; Wang J; Han A
J Pathol; 2013 Nov; 231(3):323-34. PubMed ID: 23878072
[TBL] [Abstract][Full Text] [Related]
22. PARP inhibitor combinations with high-dose vitamin C in the treatment of Ewing sarcoma: two case reports and mechanistic overview.
Adibi A; Tokat ÜM; Özgü E; Aydın E; Demiray İ; Demiray M
Ther Adv Med Oncol; 2023; 15():17588359231213841. PubMed ID: 38107827
[TBL] [Abstract][Full Text] [Related]
23. Arsenic trioxide inhibits Ewing's sarcoma cell invasiveness by targeting p38(MAPK) and c-Jun N-terminal kinase.
Zhang S; Guo W; Ren TT; Lu XC; Tang GQ; Zhao FL
Anticancer Drugs; 2012 Jan; 23(1):108-18. PubMed ID: 21946058
[TBL] [Abstract][Full Text] [Related]
24. The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit.
Landuzzi L; De Giovanni C; Nicoletti G; Rossi I; Ricci C; Astolfi A; Scopece L; Scotlandi K; Serra M; Bagnara GP; Nanni P; Lollini PL
Am J Pathol; 2000 Dec; 157(6):2123-31. PubMed ID: 11106584
[TBL] [Abstract][Full Text] [Related]
25. RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma.
Arora S; Gonzales IM; Hagelstrom RT; Beaudry C; Choudhary A; Sima C; Tibes R; Mousses S; Azorsa DO
Mol Cancer; 2010 Aug; 9():218. PubMed ID: 20718987
[TBL] [Abstract][Full Text] [Related]
26. EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A.
Nagano A; Ohno T; Shimizu K; Hara A; Yamamoto T; Kawai G; Saitou M; Takigami I; Matsuhashi A; Yamada K; Takei Y
Int J Cancer; 2010 Jun; 126(12):2790-8. PubMed ID: 19642105
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA‑34b promotes proliferation, migration and invasion of Ewing's sarcoma cells by downregulating Notch1.
Lu Q; Lu M; Li D; Zhang S
Mol Med Rep; 2018 Oct; 18(4):3577-3588. PubMed ID: 30106161
[TBL] [Abstract][Full Text] [Related]
28. Effects of baicalein on proliferation, apoptosis, migration and invasion of Ewing's sarcoma cells.
Ye C; Yu X; Zeng J; Dai M; Zhang B
Int J Oncol; 2017 Dec; 51(6):1785-1792. PubMed ID: 29039470
[TBL] [Abstract][Full Text] [Related]
29. Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma.
Lau YS; Adamopoulos IE; Sabokbar A; Giele H; Gibbons CL; Athanasou NA
Br J Cancer; 2007 Jun; 96(11):1716-22. PubMed ID: 17533390
[TBL] [Abstract][Full Text] [Related]
30. MiR-125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway.
Li J; You T; Jing J
Cell Prolif; 2014 Apr; 47(2):152-60. PubMed ID: 24517182
[TBL] [Abstract][Full Text] [Related]
31. TIPE1 inhibits the growth of Ewing's sarcoma cells by suppressing Wnt/β-catenin signaling.
Wang Z; Sun L; Liu S; Jiang H
Clin Transl Oncol; 2023 May; 25(5):1332-1339. PubMed ID: 36495466
[TBL] [Abstract][Full Text] [Related]
32. Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL).
Van Valen F; Fulda S; Truckenbrod B; Eckervogt V; Sonnemann J; Hillmann A; Rödl R; Hoffmann C; Winkelmann W; Schäfer L; Dockhorn-Dworniczak B; Wessel T; Boos J; Debatin KM; Jürgens H
Int J Cancer; 2000 Oct; 88(2):252-9. PubMed ID: 11004677
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ
J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891
[TBL] [Abstract][Full Text] [Related]
34. Survivin, a target to modulate the radiosensitivity of Ewing's sarcoma.
Greve B; Sheikh-Mounessi F; Kemper B; Ernst I; Götte M; Eich HT
Strahlenther Onkol; 2012 Nov; 188(11):1038-47. PubMed ID: 23053158
[TBL] [Abstract][Full Text] [Related]
35. Targeted therapies in Ewing's sarcoma.
Scotlandi K
Adv Exp Med Biol; 2006; 587():13-22. PubMed ID: 17163152
[TBL] [Abstract][Full Text] [Related]
36. Picropodophyllin inhibits the growth of Ewing's sarcoma cells through the insulin‑like growth factor‑1 receptor/Akt signaling pathway.
Wu YT; Wang BJ; Miao SW; Gao JJ
Mol Med Rep; 2015 Nov; 12(5):7045-50. PubMed ID: 26323364
[TBL] [Abstract][Full Text] [Related]
37. p53 and ras mutations in Ewing's sarcoma.
Radig K; Schneider-Stock R; Röse I; Mittler U; Oda Y; Roessner A
Pathol Res Pract; 1998; 194(3):157-62. PubMed ID: 9587933
[TBL] [Abstract][Full Text] [Related]
38. Comparison of cell surface antigen HBA71 (p30/32MIC2), neuron-specific enolase, and vimentin in the immunohistochemical analysis of Ewing's sarcoma of bone.
Fellinger EJ; Garin-Chesa P; Glasser DB; Huvos AG; Rettig WJ
Am J Surg Pathol; 1992 Aug; 16(8):746-55. PubMed ID: 1497115
[TBL] [Abstract][Full Text] [Related]
39. Neurogenic potential of Ewing's sarcoma cells.
Sugimoto T; Umezawa A; Hata J
Virchows Arch; 1997 Jan; 430(1):41-6. PubMed ID: 9037314
[TBL] [Abstract][Full Text] [Related]
40. Ewing's sarcoma of bone tumor cells produces MCSF that stimulates monocyte proliferation in a novel mouse model of Ewing's sarcoma of bone.
Margulies BS; DeBoyace SD; Damron TA; Allen MJ
Bone; 2015 Oct; 79():121-30. PubMed ID: 26051470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
